title: The role of peginterferon in nucleos(t)ide-analogue-treated chronic hepatitis B patients: A review of published literature.
abstract: Chronic hepatitis B infection (CHB) causes up to 1.0 million deaths annually. Currently, more than 90% of CHB patients worldwide are receiving indefinite nucleos(t)ide analogue (NA) therapy. New strategies for optimizing hepatitis B surface antigen (HBsAg) loss are required for NA-treated patients as the majority are unable to achieve HBsAg loss and may require lifelong therapy. In hepatitis B e antigen (HBeAg)-positive patients, switching from NAs to finite peginterferon (PegIFN) therapy can double HBeAg seroconversion rates. One in five patients who switch to PegIFN can achieve HBsAg loss, whereas patients who continue NA therapy typically do not. In HBeAg-negative NA-treated patients, add-on PegIFN therapy achieves higher, albeit modest, HBsAg loss rates compared with continued NA monotherapy and offers the opportunity for NA-treated patients to achieve the inactive carrier state. In the absence of curative therapies, PegIFN represents a valuable, finite option for NA-treated patients who would otherwise require potentially lifelong therapy.
authors.affiliation: Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
authors.forename: W
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
authors.forename: Q
authors.initials: Q
authors.lastname: Xie
authors.affiliation: Department of Infectious Diseases, Wuhan Tongji Hospital affiliated to Huazhong Technology University, Tongji Medical College, Wuhan, China.
authors.forename: Q
authors.initials: Q
authors.lastname: Ning
authors.affiliation: Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, China.
authors.forename: X
authors.initials: X
authors.lastname: Dou
authors.affiliation: International Medical Department, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
authors.forename: X
authors.initials: X
authors.lastname: Chen
authors.affiliation: Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
authors.forename: J
authors.initials: J
authors.lastname: Jia
authors.affiliation: Shanghai Roche Pharmaceuticals Ltd, Shanghai, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Xie
authors.affiliation: Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
authors.forename: H
authors.initials: H
authors.lastname: Ren
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D057915:Drug Substitution / Q000379:methods*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D009705:Nucleosides / Q000008:administration & dosage*; D009711:Nucleotides / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D016898:Interferon-alpha; D009705:Nucleosides; D009711:Nucleotides
keywords: HBsAg loss; chronic hepatitis B; nucleos(t)ide analogue; peginterferon